LUCIUS 卢修斯 厄达替尼 Erdafitinib尿路上皮癌

厄达替尼

美国FDA批准上市产品,疗效确切
卢修斯制药(老挝)有限公司出品

Erdafitinib

老挝国家食药监局批准上市
老挝国家药检所检测认证

Composition:
Eoel fils-cestedrabler contaiss Erdafitinb ....... A ng

LUCIUS

尿路上皮癌

IoiErda is a kinsse irhibitor indicated for the trestinent
fsdultosfieets with locally ady arted or metastatie

PHARMACEUTICALS

urotbelial carcinoma(muC)that 3as
FR.3 or FOFR2 genetic alterations and
platinun-contamung chemotherapy incladine with
months of nsoxdiuvant on s

LuciErda

chemothierapy
*Confonthe presenceofFGFR gonetic alterstions

Erdafitinib Tablets

FDA批准

*Kecommended inical dosage: 8 mg orally once daily
vith a dose incresse to 9 img datl if criterua are mel
Swallow whole with or without food.
Mtorage:ina dry place and storeat 20°Cto25°℃
Keep medicine out of reuch of Children. Do not adniniter
LuciErda during Pregnasey and Lactarien
PLEASE SEE PACKAGE INSERT

4mg

Mamnfactured and Marketed b
LUCIUS

权威认证

Thongmang village. Xasthans district. Vientiane

28 Tablets

of registered phesicians only.and as directid

Rx Only

口碑质量

适应症:
适用于治疗患有局部晚期或转移性尿路上皮癌的成年患者

推荐剂量:
起始剂量为8mg每日一次,空腹或随餐口服,在第14天和第21天
之间血磷水平低于5.5mg/dL目标值的患者,剂量增加至9mg每
日一次,直至疾病进展或无法耐受。
如果服药后发生呕吐,不可补服,下次服药仍按照原间隔时间。如
果漏服,当日内可以按量补服,下次服药仍按照原间隔时间。